Steve Ruchefsky, a graduate of the George Washington University Law School, litigated complex economic disputes during his 15-year law career. For over two decades, Ruchefsky leveraged his experience with complicated financial matters to become an active private investor and successful driver of transformative early stage businesses. Through 2017, he served as the senior executive and private investment manager for the founder and CEO of a multibillion-dollar hedge fund, and was responsible for the initial funding and development of many successful businesses and ventures. In the life sciences, Ruchefsky was responsible for the initial funding of Cougar Biotechnology Inc. (CGRB: NASDAQ), enabling the development and subsequent commercialization of Zytiga (abiraterone acetate). Cougar was subsequently acquired by Johnson & Johnson. He was an active early investor and founding director of Kite Pharma, Inc. (KITE: NASDAQ), which successfully developed the immunotherapy treatment Yescarta. Kite was acquired by Gilead Sciences in 2017. Currently, Ruchefsky is a president, CEO, and cofounder of Regel Therapeutics, a gene therapy company. He is also a partner of PhiFund Ventures, a life sciences investment fund, and founder and director of Script BioSciences and HitchBio, as well as executive chairman of MD Solar Sciences.